Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice.

Journal of Complementary Therapies in Health ISSN 2975-9323 |eISSN 2975-9552 Journal of Complementary Therapies in Health 2026:4(1). doi:10.5281/zenodo.17976742 institutoptc.com/journal-complementary-therapies Review Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. Rui Afonso1, João Veiga2, Tânia Almeida2, Jussara Araújo Barros2, and Marta Peixoto2. 1 Independent researcher; 2 IPN – Portuguese Institute of Naturology, Porto, Portugal. * Correspondence: [email protected] Abstract Background: Molybdenum (Mo) is an essential cofactor for sulphite oxidase, the enzyme responsible for converting reactive sulphites into sulphates. Functional insufficiency, driven by poor dietary intake, dysbiosis, inflammation, or genetic variants, may impair detoxification capacity and contribute to symptoms such as fatigue, headaches, bronchial reactivity, and gastrointestinal discomfort. Objectives: To synthesise current evidence on dietary, metabolic, and clinical determinants of Mo status, and to outline integrative strategies for supporting sulphite detoxification within a Naturopathic framework. Methods: This synthesis draws on biochemical, nutritional, and clinical literature addressing Mo physiology, sulphite metabolism, dietary intake patterns, genetic modifiers, and evidence-based naturopathic interventions. Emphasis is placed on functional assessment and therapeutic personalisation. Results: Findings indicate that many individuals may exhibit functional Mo insufficiency despite meeting standard reference intakes. High sulphite exposure, impaired intestinal absorption, mitochondrial dysfunction, and specific polymorphisms (e.g., sulphite oxidase, MOCS1) may reduce sulphite oxidase activity. Integrative interventions, including Mo-rich diets, reduction of exogenous sulphites, antioxidant support, and targeted supplementation, can improve metabolic resilience when deployed with laboratory supervision. Conclusions: Mo plays a pivotal role in sulphite metabolism and should be considered in patients presenting with unexplained intolerances or detoxification-related symptoms. A personalised approach that combines functional testing, nutritional optimisation, and lifestyle strategies can enhance clinical outcomes and reduce the burden of sulphite-related metabolic stress. Keywords: Molybdenum; Sulphite Oxidase; Detoxification; Functional Nutrition; Naturopathic Medicine; Sulphite Intolerance; Mitochondrial Function; Oxidative Stress; Genetic Polymorphisms. 1. Introduction 1.1. Rationale and Clinical Relevance The accumulation of sulphites in the human body is an often-neglected phenomenon, despite presenting significant repercussions for mitochondrial, neurological, respiratory, and gastrointestinal function 1,2. Sulphites arise both as endogenous by-products of sulphur amino acid metabolism and from the exogenous ingestion of food additives and drugs (E220–E228), necessitating efficient detoxification to prevent toxic effects. This process occurs mainly through the conversion of sulphites to sulphates, mediated by the enzyme sulphite oxidase, whose activity depends on Mo as an indispensable cofactor 3. Citation: Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. Journal of Complementary Therapies in Health. 2026;4(1) 10.5281/zenodo.17976742 Academic Editor: Jorge Rodrigues Received: 3 November 2025 Reviewed: 29 November 2025 Revised: 14 December 2025 Accepted: 16 December 2025 Published: 18 December 2025 Publisher’s Note: IPTC stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: ©2026 by the authors. Submitted for open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Journal of Complementary Therapies in Health 2026: 4(1). 2 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 Despite this fundamental role, Mo remains a trace element frequently underestimated in clinical practice and complementary therapeutic approaches. Its functional deficiency can compromise enzymatic activity even in the presence of normal serum concentrations, affecting multiple organ systems 4. Evidence suggests that manifestations such as persistent fatigue, headaches, intolerance to sulphite-rich foods, gastrointestinal changes, and non-specific neurological signs may reflect alterations in this metabolic pathway 5,6. The increasing environmental exposure to food additives, chemical pollutants, and sulphur compounds coincides with the rise in the prevalence of mitochondrial dysfunctions, chronic inflammatory processes, and multiple food intolerances. In this context, Mo emerges as a potential limiting factor in the body’s detoxification capacity, silently influencing biochemical homeostasis 2,7,8. Thus, the choice of the present topic proves to be scientifically pertinent and clinically strategic. The analysis of the interaction between Mo and sulphite detoxification mechanisms contributes to clarifying an under-explored area but one of growing relevance in modern Naturopathy. By integrating precision biochemistry knowledge with contemporary research, space is opened for the development of more complete and evidence-based therapeutic approaches in integrative clinical practice. Therefore, the objectives of this study are: (1) to evaluate the physiological and biochemical role of Mo in detoxification processes, with particular emphasis on its function as a cofactor for the sulphite oxidase enzyme, essential in the conversion of sulphites to sulphates; (2) to critically analyse recent scientific literature on the relationship between Mo deficiency, functional or absolute, and sulphite accumulation in the human body; (3) to investigate the clinical repercussions of dysfunction in this metabolic pathway, namely its association with systemic inflammatory processes, neurological manifestations, and sulphite-induced food intolerances; (4) to explore integrative therapeutic approaches based on functional Naturopathy, aimed at the prevention and correction of imbalances related to sulphur metabolism; and (5) to contribute to the clinical valorisation of Mo as a central element in regulating biochemical processes linked to oxidative stress, inflammation, and metabolic homeostasis. 2. Methodology This study is based on a narrative literature review, oriented to integrate biochemical, physiological, clinical, and naturopathic data related to the role of Mo in sulphite detoxification. To ensure the reliability and currency of the information, recognised scientific databases (PubMed, Scopus, Web of Science, Google Scholar, and SciELO) were consulted in the period between January 2000 and June 2025. The literature search was conducted using specific keywords, isolated or combined by Boolean operators (AND, OR), including: molybdenum, sulphite oxidase, sulphite detoxification, sulphite sensitivity, molybdenum deficiency, sulphite toxicity, molybdenum supplementation, mitochondrial dysfunction, sulphite oxidase gene, functional medicine, naturopathy detox, among others. The selection of literature for this review was governed by three specific inclusion criteria. Firstly, all included publications must demonstrate direct relevance to the biochemical mechanisms of Mo or sulphite metabolism, ensuring the focus remains on the core subject matter. Secondly, to facilitate comprehensive analysis, the publications must be available in English, French, Spanish, or Portuguese. Finally, the selected works must exhibit clear methodological quality and recognised institutional affiliation, thereby ensuring the reliability and academic rigour of the evidence considered. The following criteria were employed to exclude unsuitable literature and studies from the review: • Significant Methodological Limitations: Articles with notable flaws in design, execution, or analysis that compromise the reliability or validity of their findings were excluded. Journal of Complementary Therapies in Health 2026: 4(1). 3 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 • Opinion Publications without Experimental Foundation: Works based solely on expert opinion, conjecture, or theoretical discussion that lacked underlying experimental data or empirical evidence were not included. • Outdated or Duplicated Studies: Studies that were obsolete due to newer, more robust research or publications that were duplicates were filtered out. Priority was given to review articles, clinical trials, case studies, and original research of direct relevance, with particular attention to publications from the last 20 years. Additionally, chapters from academic books and technical documents from international organisations, such as the European Food Safety Authority (EFSA) and the World Health Organization (WHO), were included whenever considered scientifically pertinent. 3. Molybdenum in the Human Body 3.1. Role as an Essential Trace Element Mo is a trace element indispensable for human life, present in extremely small quantities in the body, but essential for the activity of several critical biochemical reactions 9. Its main role is to act as a metallic cofactor for a specific group of enzymes, the molybdoenzymes, which catalyse fundamental redox reactions in the sulphur, purine, aldehyde, and various pharmacological compound cycles 9-11. The Mo-dependent enzymes include: • Sulphite Oxidase: Converts toxic sulphites into innocuous sulphates, constituting the final stage of cysteine metabolism and preventing the accumulation of potentially harmful intermediates 12. • Xanthine Oxidase: Participates in the degradation of purines, promoting the conversion of hypoxanthine and xanthine into uric acid, a relevant plasma antioxidant, but which in excess is associated with hyperuricaemia and gout 13. • Aldehyde Oxidase: Acts in the oxidation of endogenous and xenobiotic aldehydes, playing an important role in drug metabolism and the elimination of potentially toxic compounds 9,14. Mo integrates these enzymes through the molybdopterin cofactor, an organic structure that incorporates the metallic ion and allows the electronic transfer necessary for enzymatic catalysis 15,16. In the absence of this functional cofactor, the activity of molybdoenzymes is severely compromised, leading to the accumulation of toxic substrates and significant metabolic disturbances. Although absolute Mo deficiency is considered rare in healthy individuals, functional deficiencies are increasingly described in the literature. These can result from insufficient intake, poor intestinal absorption, competition with other minerals, or increased metabolic utilisation in states of chronic inflammation. Conditions such as intestinal dysbiosis, industrialised diets poor in trace elements, and states of high oxidative stress can contribute to this functional deficit 4,17. From an integrative clinical perspective, Mo assumes relevance not only for its isolated enzymatic role but also for the systemic impact it exerts. Through the metabolic pathways in which it participates, it influences sulphur metabolism 12, the modulation of oxidative stress 13, hepatic detoxification processes 9,14, and the regulation of neurological and mitochondrial functions 11, standing out as a key micronutrient in global biochemical homeostasis 4. 3.2. Mechanisms of Absorption, Transport, and Storage Mo absorption occurs predominantly in the small intestine, especially in the jejunum, through mechanisms that are still not fully clarified. Evidence suggests that the process involves facilitated passive transport and, to a lesser extent, active transport dependent on ionic gradients 18. The bioavailability of Mo is high, ranging between 80% and 90% Journal of Complementary Therapies in Health 2026: 4(1). 4 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 when ingested in soluble forms such as sodium molybdate, which makes it one of the most efficiently assimilated trace elements by the human body 4. After absorption, Mo circulates in the plasma mainly as free molybdate, although it also transiently associates with albumin and other plasma proteins 9,14. Metabolically active tissues rapidly capture this trace element, with intracellular transport dependent on mechanisms that are still poorly characterised, possibly involving anionic channels and specific transporters 19,20. In the intracellular environment, Mo is incorporated into the molybdopterin complex, its functional form, which acts as a cofactor for the molybdoenzymes 11. The synthesis of the Mo cofactor (MoCo) depends on a specialised biochemical pathway, which requires the participation of specific enzymes and the availability of elements such as sulphur and iron. Thus, genetic, metabolic, or nutritional deficits of these cofactors can compromise Mo-dependent enzymatic activity, even when serum levels are within the normal range 21,22. Unlike minerals such as iron and zinc, Mo does not have significant body reserves. The main sites of temporary accumulation include the liver, kidneys, adrenal glands, and, to a lesser extent, the brain and mitochondria, reflecting the high biochemical needs of these tissues 13. Mo homeostasis is regulated primarily via the renal route, through urinary excretion. This feature ensures the efficient elimination of excesses and contributes to its low toxicity potential in healthy individuals. However, it also means that chronic urinary losses, poor intestinal absorption, or changes in the microbiota can lead to subclinical states of deficiency, especially in situations of inflammatory bowel disease, alcoholism, severe dysbiosis, or restrictive diets 17. 3.3. Active Forms: Enzymatic Cofactors The biological activity of Mo depends on its incorporation into specific enzymatic complexes, where it acts as a central atom in oxidation-reduction reactions. To perform its catalytic function, inorganic Mo absorbed in the form of molybdate (MoO42−), needs to be converted into the Mo cofactor, resulting from the association of the metallic ion with an organic structure called molybdopterin. This process occurs through a complex and evolutionarily conserved biosynthetic pathway 11,22. Mo cofactor is indispensable for the activity of four human enzymes: • Sulphite Oxidase: Catalyses the oxidation of sulphites to sulphates, an essential step in cysteine metabolism and the prevention of oxidative stress 23,24. • Xanthine Oxidase: Converts hypoxanthine and xanthine into uric acid, regulating purine degradation and contributing to antioxidant mechanisms and pathological conditions such as gout 25,26. • Aldehyde Oxidase: Intervenes in the oxidation of endogenous and xenobiotic aldehydes, including pharmacological metabolites 27-29. • Mitochondrial Amidoxime Reducing Component: More recently identified, this enzyme is involved in the reduction of nitrogenous compounds and the modulation of reactive species 30-32. The absence of functional Mo or mutations affecting MoCo biosynthesis results in severe enzymatic deficiencies 33,34. A paradigmatic example is congenital sulphite oxidase deficiency, a rare but fatal metabolic disorder in neonates due to the accumulation of sulphites and subsequent neurotoxicity 35,36. Although hereditary cases are uncommon, functional or partial forms of deficiency, associated with states of intestinal dysbiosis, chronic intoxications, persistent inflammation, or malnutrition, are more prevalent and often under-diagnosed 37-40. Journal of Complementary Therapies in Health 2026: 4(1). 5 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 From a naturopathic perspective, the recognition of these functional deficiencies is fundamental for understanding diffuse clinical manifestations, food intolerances, and chronic conditions that do not respond to conventional therapies 17. 3.4. Excretion and Homeostatic Regulation Mo homeostasis is ensured primarily by renal excretion, which regulates the balance between intestinal absorption and elimination, preventing both deficiency and toxicity. The mineral circulates in the plasma predominantly as free molybdate, being filtered in the glomeruli and excreted proportionally to its serum concentration and hydration status 41,42. Unlike minerals such as iron or copper, Mo does not have robust intracellular storage systems. Transient reserves are located mainly in the liver, kidneys, making the body dependent on a continuous dietary intake 13. Homeostasis is thus highly vulnerable in situations of nutritional deficiency, intestinal dysfunction, chronic renal failure, or excessive urinary losses 17,43. Reference plasma values range between 0.3 and 2.0μg/dL, although there is considerable inter-laboratory variability and a lack of clinical standardisation 44. Furthermore, normal serum concentrations do not exclude functional deficiencies, given that enzymatic activity depends on the integration of Mo into MoCo 11. Faecal excretion represents a secondary route, more relevant in cases of low intestinal absorption or excessive ingestion, while elimination via sweating appears to be insignificant 18. Regulation is non-hormonal but adaptive: sudden increases in intake result in greater urinary excretion, which explains its low acute toxicity. However, this same characteristic can lead to silent depletions in chronic marginal intake, aggravated by intestinal dysbiosis, chronic inflammation, or excessive alcohol consumption 37,45,46. In functional clinical practice, the assessment of Mo status should consider not only plasma levels but also indirect markers, such as urinary sulphite excretion, indicators of oxidative stress, liver enzymes, and glutathione, in order to obtain a more reliable perspective on the functional status of the mineral 43. 4. Sulphites: Sources, Exposure, and Effects 4.1. Endogenous vs. Exogenous Sulphites Sulphites are present in the human body in two main forms: endogenous, produced as a physiological by-product of metabolic processes, and exogenous, resulting from the ingestion of food additives, drugs, and environmental exposures. This distinction is fundamental for evaluating the total sulphite load and the individual efficiency of detoxification mechanisms 5,47,48. Endogenous Sulphites: By-products of Cellular Metabolism Endogenous sulphites are generated mainly during the metabolism of sulphur amino acids, especially cysteine and, to a lesser extent, methionine. In the process of deamination and desulphurisation of cysteine, sulphur is initially converted into sulphite (SO32−), which is subsequently oxidised into sulphate (SO42−), by the enzyme sulphite oxidase. This step is essential to prevent the accumulation of toxic and unstable intermediates 9,49. This mechanism occurs continuously in tissues with high metabolic activity, such as the liver, kidneys, and brain, and is closely linked to the methionine-glutathione cycle, which is fundamental in antioxidant defence and hepatic detoxification processes. However, when sulphite oxidase activity is reduced, either due to Mo deficiency or intense oxidative stress, sulphite accumulation can induce metabolic dysfunctions and promote cellular inflammation 48,50,51. Journal of Complementary Therapies in Health 2026: 4(1). 6 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 Exogenous Sulphites: Preservatives and Potential Risks Exogenous sulphites are widely used as food additives (E220–E228) due to their antimicrobial, antioxidant, and bleaching properties. They are found in wines, dried fruits, frozen shrimp, processed potatoes, soft drinks, industrial sauces, and some drugs 52. In individuals with reduced sulphite oxidase activity or under high cumulative toxic load, sulphite ingestion can exceed the body's detoxification capacity, leading to its accumulation in the blood, tissues, and mitochondria 5. Repeated exposure to these compounds has been associated with headaches, persistent fatigue, bronchospasms, gastrointestinal disturbances, and urticaria. In more severe cases, manifestations similar to asthma attacks or episodes of transient neurological dysfunction may occur 53,54. These clinical manifestations are often misinterpreted, being attributed to non-specific food intolerances or psychosomatic conditions 5,54. 4.2. Detoxification Capacity: An Individual Limit The efficiency of sulphite detoxification varies widely among individuals and depends on factors such as sulphite oxidase expression, Mo availability, the integrity of the intestinal mucosa, and the total xenobiotic load. Genetics (e.g., sulphite oxidase gene polymorphisms), diet, the composition of the intestinal microbiota, alcohol consumption, chronic use of medications, and the presence of inflammatory or liver diseases are determinants in this process 55. Thus, the balance between endogenous production and elimination of sulphites must be understood not only as a biochemical mechanism but also as an indicator of metabolic resilience. This parameter also constitutes a strategic target in naturopathic intervention, especially in conditions of chronic fatigue, multiple hypersensitivities, and low-grade inflammation 55. 4.3. Food, Pharmacological, and Environmental Sources Exogenous exposure to sulphites is an omnipresent reality in contemporary society, resulting from the consumption of industrialised foods, use in pharmaceutical preparations, and presence in environmental pollutants. This external load adds to the physiological endogenous production and can exceed the detoxification capacity, especially in individuals with reduced sulphite oxidase enzyme activity 5,47,52. Food Sources Sulphites are authorised as food additives under codes E220 to E228, performing antimicrobial, antioxidant, and bleaching functions 52. They are particularly present in the following foods: • Wines, sparkling wines, and ciders – sulphur dioxide is added for microbiological stabilisation and oxidation prevention. • Treated dried fruits (apricots, raisins, figs) – often preserved with sodium metabisulphite 56. • Processed potatoes – in the form of chips, frozen products, or industrial mash, where sulphites prevent enzymatic browning 5. • Frozen seafood (particularly shrimp) – where sulphites inhibit enzymatic melanin reactions 52. • Juices, industrial sauces, jams, pickles, and bakery products – frequently subjected to sulphite addition to prolong stability. Studies indicate that, in susceptible individuals, the ingestion of doses higher than 10mg of sulphites per meal can trigger adverse reactions, including headaches, fatigue, gastric irritation, and respiratory symptoms 5. Journal of Complementary Therapies in Health 2026: 4(1). 7 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 Pharmacological Sources Sulphites are also used as preservative excipients in various drugs, especially in injectable and inhaled formulations. The most relevant examples include: • Injectable adrenaline (epinephrine) – frequently stabilised with metabisulphite 5,57. • Injectable or inhalable corticosteroids, such as methylprednisolone and budesonide 56. • Inhaled bronchodilators, used in asthma attacks, which paradoxically may contain sulphites as stabilisers 58. • Local anaesthetics and intravenous antibiotics, in which sulphites act as formulation preservatives. These forms of exposure are clinically relevant in asthmatic patients or individuals with enzymatic deficits, potentially triggering bronchospasms, urticaria, or anaphylactoid reactions 52,58. Environmental Sources Although less publicised, environmental sources represent an additional route of exposure: • Industrial emissions (refineries, paper mills, textile industries), which release sulphur dioxide (SO2), subsequently converted into endogenous sulphites in the lungs 59,60. • 61,62. • Contaminated indoor environments, such as spaces with mould or a high load of volatile organic compounds, which can compromise antioxidant defence and liver function 63,64. Chronic exposure to environmental sulphites has been associated with the exacerbation of inflammatory symptoms and the worsening of multiple chemical sensitivity conditions, especially in individuals with compromised mitochondrial and hepatic reserves 65-67. 4.4. Toxic Effects and Systemic Impact The accumulation of sulphites in the human body can trigger multiple toxic effects at the cellular and systemic level, affecting mainly tissues with high mitochondrial activity and greater vulnerability to oxidative stress, such as the lungs, liver, brain, and gastrointestinal tract 5,68,69. This toxicity largely results from the formation of reactive oxygen species (ROS) during the incomplete oxidation of sulphites, as well as their ability to interfere with cellular enzymes and lipid structures 50,70-72. Experimental studies demonstrate that sulphites (even at concentrations considered safe by regulatory authorities, can induce lipid peroxidation, DNA damage, cellular apoptosis, and mitochondrial dysfunction) effects exacerbated in the presence of deficiencies of Mo, selenium, or glutathione, essential nutrients for neutralising oxidative stress 73,74. Clinically, high or chronic exposure to sulphites has been associated with systemic manifestations, including: • Recurrent headaches, persistent fatigue, and difficulty concentrating 56. • Respiratory symptoms, such as bronchospasm, dry cough, wheezing, and chest tightness, especially in asthmatics 5. • Gastrointestinal changes, including nausea, cramps, diarrhoea, and reflux, attributed to irritation of the intestinal mucosa 52. • Cutaneous manifestations, such as urticaria, pruritus, and rashes, often of a pseudoallergic nature 57,66. Journal of Complementary Therapies in Health 2026: 4(1). 8 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 • Systemic mitochondrial dysfunction, expressed as chronic fatigue, exercise intolerance, and cognitive changes 75,76. In the nervous system, recent evidence suggests that sulphites can interfere with glutamatergic neurotransmission and the activity of glial cells, promoting states of low-grade neurogenic inflammation, with possible implication in neurodegenerative diseases 77,78. In animal models, sulphite exposure induced behavioural changes, neuronal loss, and dysfunction of the blood-brain barrier, effects attenuated after supplementation with Mo and antioxidants 79,80. It is important to note that sulphite toxicity depends not only on the dose ingested or inhaled but also on the individual's capacity for metabolism, modulated by factors such as genetic polymorphisms (e.g., mutations in the sulphite oxidase gene), liver status, intestinal microbiota composition, diet, and co-exposure to other xenobiotics 58,81-84. Thus, sulphite accumulation must be understood as a cumulative functional risk factor, whose clinical evaluation and management benefit from an integrative and personalised approach, in line with the principles of contemporary functional Naturopathy. 4.5. International Regulation (E220–E228) Sulphites are internationally regulated as authorised food additives, classified under codes E220 to E228, which include compounds such as sulphur dioxide (E220), sodium, potassium, and calcium sulphites, metabisulphites, and hydrogen sulphites. These compounds are widely applied in the food and pharmaceutical industries due to their antioxidant, antimicrobial, and preservative properties, and are considered technologically indispensable in various products 52. The European Food Safety Authority (EFSA) established, in 2021, an Acceptable Daily Intake (ADI) for sulphites of 0.7mg/kg of body weight per day (expressed as sulphur dioxide). This value was determined based on toxicological studies, clinical trials, and evidence of adverse effects in humans and animals 52. The dose was defined to be safe for the majority of the population, including children and adults who are regular consumers of processed foods. However, population assessments have shown that certain groups can easily exceed the ADI, especially when ingesting several sulphite-rich foods on the same day, such as wine, dried fruits, and industrial sauces 85-87. Furthermore, individuals with reduced sulphite oxidase enzyme activity, including asthmatics, alcoholics, people with intestinal dysbiosis, or functional Mo deficiency, may manifest adverse reactions even with intakes lower than the dose considered safe 88-90. In the United States, the Food and Drug Administration (FDA) requires mandatory labelling whenever the sulphite concentration exceeds 10ppm (parts per million). In the European Union, declaration is mandatory above 10mg/kg or 10mg/L, depending on the type of product 91,92. Despite these measures, the majority of consumers remain poorly informed about their accumulated exposure to sulphites, especially when they regularly consume processed foods 93-95. From a regulatory point of view, sulphites are considered safe in low doses. However, this assessment is based on population averages, not adequately contemplating individual vulnerabilities, such as genetic predisposition, states of chronic inflammation, and cumulative oxidative stress. Furthermore, the interaction with metabolic and environmental factors is not fully integrated into legal limits 96-99. 4.6. Naturopathic Perspective and Integrative Proposal Sulphite toxicity does not depend exclusively on the ingested dose, but above all on the individual capacity for metabolism and elimination. In this framework, the concept of “sulphite intolerance” can be reinterpreted as an acquired or constitutional metabolic dysfunction, potentially reversible with adequate support for detoxification and redox balance 5,100. Journal of Complementary Therapies in Health 2026: 4(1). 9 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 The accumulation of sulphites can be understood as an indirect biomarker of toxic overload, enzymatic cofactor deficiency, or hepato-mitochondrial dysfunction. These states are rarely detected in conventional laboratory tests, which contributes to their undervaluation in standard clinical settings 6,101,102. Key strategies proposed in this area include: • Reduction of the exogenous sulphite load by eliminating or rotating industrialised foods and beverages containing additives E220, E228}, including wine, dried fruits, seafood, and commercial sauces 52,103,104. • Reinforcement of endogenous enzymatic capacity through Mo supplementation, with the goal of restoring sulphite oxidase activity, especially in individuals with chronic fatigue, recurrent headaches, or multiple hypersensitivities 31,36,79. • Mitochondrial and Antioxidant Support, using compounds such as glutathione, Nacetylcysteine (NAC), selenium, Coenzyme Q10 (CoQ10), and B vitamins, which mitigate the oxidative stress induced by sulphite accumulation 105-108. • Correction of intestinal dysbiosis, as this can compromise the absorption of Mo, the biosynthesis of molybdopterin, and hepatic conjugation mechanisms, exacerbating the effects of sulphites even at moderate intake 31,109,110. • Individualised dietary planning, based on chrononutrition principles, anti-inflammatory strategies, and symptom monitoring after consuming sulphite-rich foods, particularly in individuals with low detoxification resilience 111-114. The monitoring of the clinical response should include symptom scales and complementary laboratory tests, such as urinary sulphite, plasma markers of oxidative stress, and reduced glutathione, as well as the evaluation of indirect signs, such as fatigue, abdominal distension, eczema, and alcohol intolerance 115-120. 5. Sulphite Oxidase: The Molybdenum-Dependent Key Enzyme 5.1. Structure and Function Sulphite Oxidase is the terminal enzyme in the catabolism of sulphurous amino acids in mammals, catalysing the oxidation of sulphite (SO₃²⁻) to sulphate (SO₄²⁻), an indispensable step to prevent the accumulation of toxic intermediates, such as cysteine, and to preserve cellular integrity 121-124. In eukaryotic cells, it is located in the mitochondrial intermembrane space, where it executes the reaction SO₃²⁻ + H₂O → SO₄²⁻ + 2H⁺ + 2e⁻ and transfers the released electrons to cytochrome c, coupling sulphite detoxification to the respiratory chain 7. Structurally, sulphite oxidase is a homodimer; each monomer contains two catalytic centres: (i) an N-terminal heme-b₄ domain for electron transfer, and (ii) a C-terminal domain with Mo coordinated to the Mo cofactor inserted into molybdopterin, where sulphite oxidation occurs 7,125-127. The intracatalytic electron flow proceeds from the Mo centre to the heme and then to exogenous cytochrome c, which re-oxidises the enzyme and delivers electrons to Complex IV, integrating it into energy metabolism 31,128,129. The maturation of sulphite oxidase is cofactor-dependent: import into the mitochondrion requires a bipartite signal sequence, and MoCo binding is necessary for retention in the intermembrane space; without MoCo, the processed protein may remain in the cytosol and not reach the functional state 130-133. Furthermore, heme insertion and dimerisation occur after MoCo integration, in a hierarchy that ensures correct folding and activity 134. The strict dependence on Mo stems from the fact that the metallic atom in MoCo alternates between oxidation states during the catalytic cycle, allowing the transfer of oxygen to the substrate and the subsequent sequential transfer of two electrons to the heme/cytochrome c 31,135. In mammals, sulphite oxidase exhibits highest expression in the liver, kidney, and heart, reflecting the detoxification and metabolic demands of these tissues 7,136-138. Journal of Complementary Therapies in Health 2026: 4(1). 16 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 23. Boyer M, Sowa M, Wang R, Abdenur J. Isolated Sulfite Oxidase Deficiency: Response to Dietary Treatment in a Patient with Severe Neonatal Presentation. Journal of Inborn Errors of Metabolism and Screening. 2019;7. 24. Reiss J. Molybdenum Cofactor and Sulfite Oxidase Deficiency. Journal of Postgenomics Drug & Biomarker Development. 2016;6(3). doi: https://doi.org/10.4172/2153-0769.1000184 25. Brondino CD, Romao MJ, Moura I, Moura JJ. Molybdenum and tungsten enzymes: the xanthine oxidase family. Curr Opin Chem Biol. 2006;10(2):109-14. doi: https://doi.org/10.1016/j.cbpa.2006.01.034 26. Battelli MG, Polito L, Bortolotti M, Bolognesi A. Xanthine Oxidoreductase-Derived Reactive Species: Physiological and Pathological Effects. Oxid Med Cell Longev. 2016;2016:3527579. doi: https://doi.org/10.1155/2016/3527579 27. Terao M, Garattini E, Romao MJ, Leimkuhler S. Evolution, expression, and substrate specificities of aldehyde oxidase enzymes in eukaryotes. J Biol Chem. 2020;295(16):5377-89. doi: https://doi.org/10.1074/jbc.REV119.007741 28. Terao M, Romao MJ, Leimkuhler S, Bolis M, Fratelli M, Coelho C, et al. Structure and function of mammalian aldehyde oxidases. Arch Toxicol. 2016;90(4):753-80. doi: https://doi.org/10.1007/s00204-016-1683-1 29. Hutzler JM, Obach RS, Dalvie D, Zientek MA. Strategies for a comprehensive understanding of metabolism by aldehyde oxidase. Expert Opin Drug Metab Toxicol. 2013;9(2):153-68. doi: https://doi.org/10.1517/17425255.2013.738668 30. Rixen S, Havemeyer A, Tyl-Bielicka A, Pysniak K, Gajewska M, Kulecka M, et al. Mitochondrial amidoxime-reducing component 2 (MARC2) has a significant role in N-reductive activity and energy metabolism. J Biol Chem. 2019;294(46):17593-602. doi: https://doi.org/10.1074/jbc.RA119.007606 31. Adamus JP, Ruszczynska A, Wyczalkowska-Tomasik A. Molybdenum's Role as an Essential Element in Enzymes Catabolizing Redox Reactions: A Review. Biomolecules. 2024;14(7). doi: https://doi.org/10.3390/biom14070869 32. Plitzko B, Ott G, Reichmann D, Henderson CJ, Wolf CR, Mendel R, et al. The involvement of mitochondrial amidoxime reducing components 1 and 2 and mitochondrial cytochrome b5 in N-reductive metabolism in human cells. J Biol Chem. 2013;288(28):20228-37. doi: https://doi.org/10.1074/jbc.M113.474916 33. Leimkühler S. The biosynthesis of the molybdenum cofactors in Escherichia coli. Environmental Microbiology. 2020;22(6):200726. 34. Atwal PS, Scaglia F. Molybdenum cofactor deficiency. Mol Genet Metab. 2016;117(1):1-4. doi: https://doi.org/10.1016/j.ymgme.2015.11.010 35. Zaki MS, Selim L, El-Bassyouni HT, Issa MY, Mahmoud I, Ismail S, et al. Molybdenum cofactor and isolated sulphite oxidase deficiencies: Clinical and molecular spectrum among Egyptian patients. Eur J Paediatr Neurol. 2016;20(5):714-22. doi: https://doi.org/10.1016/j.ejpn.2016.05.011 36. Johannes L, Fu C-Y, Schwarz G. Molybdenum Cofactor Deficiency in Humans. Molecules [Internet]. 2022; 27(20):[6896 p.]. doi: https://doi.org/10.3390/molecules27206896 37. Oskarsson A, Kippler M. Molybdenum - a scoping review for Nordic Nutrition Recommendations 2023. Food Nutr Res. 2023;67. doi: https://doi.org/10.29219/fnr.v67.10326 38. Carias Dominguez AM, de Jesus Rosa Salazar D, Stefanolo JP, Cruz Serrano MC, Casas IC, Zuluaga Pena JR. Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping Review. Probiotics Antimicrob Proteins. 2025;17(1):440-9. doi: https://doi.org/10.1007/s12602-024-10353-w 39. Quesada-Vazquez S, Bone C, Saha S, Triguero I, Colom-Pellicer M, Aragones G, et al. Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors' Combination. International journal of molecular sciences. 2022;23(22). doi: https://doi.org/10.3390/ijms232213675 40. Razzaque MS, Wimalawansa SJ. Minerals and Human Health: From Deficiency to Toxicity. Nutrients [Internet]. 2025; 17(3):[454 p.]. doi: https://doi.org/10.3390/nu17030454 41. Thompson KH, Turnlund JR. Kinetic model of molybdenum metabolism developed from dual stable isotope excretion in men consuming a low molybdenum diet. J Nutr. 1996;126(4):963-72. doi: https://doi.org/10.1093/jn/126.4.963 Journal of Complementary Therapies in Health 2026: 4(1). 17 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 42. Substances AfT, Registry D. Chapter 3. Toxicokinetics, Susceptible Populations, Biomarkers, Chemical Interactions. Agency for Toxic Substances and Disease Registry Atlanta; 2017. 43. Ross AC, Caballero B, Cousins RJ, Tucker KL, Ziegler TR. Modern nutrition in health and disease: Eleventh edition2012. 1-1616 p. 44. Barceloux DG. Molybdenum. J Toxicol Clin Toxicol. 1999;37(2):231-7. doi: https://doi.org/10.1081/clt-100102422 45. Turnlund JR, Keyes WR, Peiffer GL. Molybdenum absorption, excretion, and retention studied with stable isotopes in young men at five intakes of dietary molybdenum. Am J Clin Nutr. 1995;62(4):790-6. doi: https://doi.org/10.1093/ajcn/62.4.790 46. Intakes SCotSEoDR, Interpretation So, Intakes UoDR, Nutrients SoURLo, Micronutrients Po. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc: National Academies Press; 2002. 0309072905. 47. Kimura Y, Shibuya N, Kimura H. Sulfite protects neurons from oxidative stress. Br J Pharmacol. 2019;176(4):571-82. doi: https://doi.org/10.1111/bph.14373 48. Bai J, Lei P, Zhang J, Zhao C, Liang R. Sulfite exposure-induced hepatocyte death is not associated with alterations in p53 protein expression. Toxicology. 2013;312:142-8. doi: https://doi.org/10.1016/j.tox.2013.08.004 49. Kisker C, Schindelin H, Rees DC. Molybdenum-cofactor-containing enzymes: structure and mechanism. Annu Rev Biochem. 1997;66:233-67. doi: https://doi.org/10.1146/annurev.biochem.66.1.233 50. Maiti BK. Cross-talk Between (Hydrogen)Sulfite and Metalloproteins: Impact on Human Health. Chemistry. 2022;28(23):e202104342. doi: https://doi.org/10.1002/chem.202104342 51. Grings M, Moura AP, Amaral AU, Parmeggiani B, Gasparotto J, Moreira JC, et al. Sulfite disrupts brain mitochondrial energy homeostasis and induces mitochondrial permeability transition pore opening via thiol group modification. Biochim Biophys Acta. 2014;1842(9):1413-22. doi: https://doi.org/10.1016/j.bbadis.2014.04.022 52. EFSA. Scientific Opinion on the re-evaluation of sulfur dioxide (E 220), sodium sulfite (E 221), sodium bisulfite (E 222), sodium metabisulfite (E 223), potassium metabisulfite (E 224), calcium sulfite (E 226), calcium bisulfite (E 227) and potassium bisulfite (E 228) as food additives. EFSA Journal. 2016;14(4):4438. doi: https://doi.org/10.2903/j.efsa.2016.4438 53. Marenco Arellano V, Reano Martos M, Rodriguez Cabreros M, Bueso Fernandez A, Garcia Loria J, Rodriguez Mosquera M. Sulfite sensitivity in a patient with allergic asthma. Allergol Immunopathol (Madr). 2011;39(5):306-7. doi: https://doi.org/10.1016/j.aller.2010.07.005 54. Zhang X, Vincent AS, Halliwell B, Wong KP. A mechanism of sulfite neurotoxicity: direct inhibition of glutamate dehydrogenase. J Biol Chem. 2004;279(41):43035-45. doi: https://doi.org/10.1074/jbc.M402759200 55. Martin AM, Sun EW, Rogers GB, Keating DJ. The Influence of the Gut Microbiome on Host Metabolism Through the Regulation of Gut Hormone Release. Front Physiol. 2019;10:428. doi: https://doi.org/10.3389/fphys.2019.00428 56. Taylor SL, Higley NA, Bush RK. Sulfites in foods: uses, analytical methods, residues, fate, exposure assessment, metabolism, toxicity, and hypersensitivity. Adv Food Res. 1986;30:1-76. doi: https://doi.org/10.1016/s0065-2628(08)60347-x 57. Simon RA. Adverse reactions to drug additives. J Allergy Clin Immunol. 1984;74(4 Pt 2):623-30. doi: https://doi.org/10.1016/0091-6749(84)90116-7 58. Vally H, Misso NL, Madan V. Clinical effects of sulphite additives. Clin Exp Allergy. 2009;39(11):1643-51. doi: https://doi.org/10.1111/j.1365-2222.2009.03362.x 59. Meng Z, Qin G, Zhang B, Geng H, Bai Q, Bai W, et al. Oxidative damage of sulfur dioxide inhalation on lungs and hearts of mice. Environ Res. 2003;93(3):285-92. doi: https://doi.org/10.1016/s0013-9351(03)00045-8 60. Gutor SS, Salinas RI, Nichols DS, Bazzano JMR, Han W, Gokey JJ, et al. Repetitive Sulfur Dioxide Exposure in Mice Models Post-Deployment Respiratory Syndrome. bioRxiv. 2023:2023.05.15.540867. doi: https://doi.org/10.1101/2023.05.15.540867 61. Wiese A. Biomass Combustion for Electricity Generation. In: Kaltschmitt M, Themelis NJ, Bronicki LY, Söder L, Vega LA, editors. Renewable Energy Systems. New York, NY: Springer New York; 2013. p. 290-327. 978-1-4614-5819-7 Journal of Complementary Therapies in Health 2026: 4(1). 18 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 978-1-4614-5820-3. 62. Kosowska-Golachowska M, Luckos A, Kijo-Kleczkowska A. Pollutant Emissions during Oxy-Fuel Combustion of Biomass in a Bench Scale CFB Combustor. Energies [Internet]. 2022; 15(3):[706 p.]. doi: https://doi.org/10.3390/en15030706 63. Kumar P, Kausar MA, Singh AB, Singh R. Biological contaminants in the indoor air environment and their impacts on human health. Air Qual Atmos Health. 2021;14(11):1723-36. doi: https://doi.org/10.1007/s11869-021-00978-z 64. Al Hallak M, Verdier T, Bertron A, Roques C, Bailly JD. Fungal Contamination of Building Materials and the Aerosolization of Particles and Toxins in Indoor Air and Their Associated Risks to Health: A Review. Toxins (Basel). 2023;15(3). doi: https://doi.org/10.3390/toxins15030175 65. Chandra M, Branco P, Prista C, Malfeito-Ferreira M. Role of p-Coumaric Acid and Micronutrients in Sulfur Dioxide Tolerance in Brettanomyces bruxellensis. Beverages [Internet]. 2023; 9(3):[69 p.]. doi:10.3390/beverages9030069 66. Traub M. 222-Urticaria. Textbook of Natural Medicine (Fifth Edition). 2020:1821-33. 67. Gad SC. Sulfites. 2014. 68. Danisman B, Akcay G, Gokcek-Sarac C, Kantar D, Aslan M, Derin N. The Role of Acetylcholine on the Effects of Different Doses of Sulfite in Learning and Memory. Neurochem Res. 2022;47(11):3331-43. doi: https://doi.org/10.1007/s11064-022-03684-z 69. Hundallah K, Jabari M. Sulfite oxidase deficiency: Neurosciences (Riyadh). 2016 Oct;21(4):376-8. 1319-6138 (Print). 70. Kappler U, Bernhardt PV, Kilmartin J, Riley MJ, Teschner J, McKenzie KJ, et al. SoxAX cytochromes, a new type of heme copper protein involved in bacterial energy generation from sulfur compounds. J Biol Chem. 2008;283(32):22206-14. doi: https://doi.org/10.1074/jbc.M800315200 71. Simon J, Kroneck PM. Microbial sulfite respiration. Adv Microb Physiol. 2013;62:45-117. doi: https://doi.org/10.1016/B978-0-12410515-7.00002-0 72. Twarog FJ, Leung DY. Anaphylaxis to a component of isoetharine (sodium bisulfite). JAMA. 1982;248(16):2030-1. 73. Gunnison AF. Sulphite toxicity: a critical review of in vitro and in vivo data. Food Cosmet Toxicol. 1981;19(5):667-82. doi: https://doi.org/10.1016/0015-6264(81)90519-8 74. Kocamaz E, Adiguzel E, Gundogdu G, Kucukatay V. Sulfite leads to neuron loss in the hippocampus of both normal and SOXdeficient rats. Neurochemistry international. 2012;61(3):341-6. 75. Yang WH, Purchase EC. Adverse reactions to sulfites. CMAJ. 1985;133(9):865-7, 80. 76. Santos CVA, da Silva MG, Cabrita MJ. Impact of SO2 and bentonite addition during fermentation on volatile profile of two varietal white wines. LWT. 2020;133:109893. 77. Otto N, Marelja Z, Schoofs A, Kranenburg H, Bittern J, Yildirim K, et al. The sulfite oxidase Shopper controls neuronal activity by regulating glutamate homeostasis in Drosophila ensheathing glia. Nat Commun. 2018;9(1):3514. doi: https://doi.org/10.1038/s41467-018-05645-z 78. Wyse ATS, Grings M, Wajner M, Leipnitz G. The Role of Oxidative Stress and Bioenergetic Dysfunction in Sulfite Oxidase Deficiency: Insights from Animal Models. Neurotox Res. 2019;35(2):484-94. doi: https://doi.org/10.1007/s12640-018-9986-z 79. Glanzel NM, Parmeggiani B, Grings M, Seminotti B, Brondani M, Bobermin LD, et al. Myelin Disruption, Neuroinflammation, and Oxidative Stress Induced by Sulfite in the Striatum of Rats Are Mitigated by the pan-PPAR agonist Bezafibrate. Cells. 2023;12(12). doi: https://doi.org/10.3390/cells12121557 80. Li L, Ran Y, Shen X. Molybdenum-Induced Oxidative and Inflammatory Injury and Metabolic Pathway Disruption in Goat Pancreas. Metabolites [Internet]. 2025; 15(8):[541 p.]. doi: https://doi.org/10.3390/metabo15080541 81. Sharawat IK, Saini L, Singanamala B, Saini AG, Sahu JK, Attri SV, et al. Metabolic crisis after trivial head trauma in late-onset isolated sulfite oxidase deficiency: Report of two new cases and review of published patients. Brain Dev. 2020;42(2):157-64. doi: https://doi.org/10.1016/j.braindev.2019.11.003 82. Vaccarezza M, Vitale M, Falletta P, di Martino O. Natural Sulfur Compounds in Mineral Waters: Implications for Human Health and Disease. International journal of molecular sciences. 2025;26(21). doi: https://doi.org/10.3390/ijms262110807 Journal of Complementary Therapies in Health 2026: 4(1). 19 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 83. Zhang J, Song S, He L, Li AJ, You J, Zhang T. Transformation Products of Neonicotinoids: A Review of Human Exposure, Toxicity, and Health Risks. Environ Sci Technol. 2025;59(34):17933-51. doi: https://doi.org/10.1021/acs.est.5c00372 84. Lash LH. Trichloroethylene: An Update on an Environmental Contaminant with Multiple Health Effects. Annual review of pharmacology and toxicology. 2025;65(1):507-27. doi: https://doi.org/10.1146/annurev-pharmtox-022724-120525 85. Wu W, Fu G, Xuan R, Zhai L, Lu Y, Tang M, et al. Food additive sodium bisulfite induces intracellular imbalance of biothiols levels in NCM460 colonic cells to trigger intestinal inflammation in mice. Toxicol Lett. 2022;359:73-83. doi: https://doi.org/10.1016/j.toxlet.2022.01.019 86. Leclercq C, Molinaro MG, Piccinelli R, Baldini M, Arcella D, Stacchini P. Dietary intake exposure to sulphites in Italy--analytical determination of sulphite-containing foods and their combination into standard meals for adults and children. Food Addit Contam. 2000;17(12):979-89. doi: https://doi.org/10.1080/02652030010014402 87. DeVries JH, Gough SC, Kiljanski J, Heinemann L. Biosimilar insulins: a European perspective. Diabetes Obes Metab. 2015;17(5):445-51. doi: https://doi.org/10.1111/dom.12410 88. Edris SN, Tayel A, Hamad A. Respiratory Response to Food Safety Hazards. In: Sarkar T, Hamad A, Chatterjee A, editors. Physiological Perspectives on Food Safety: Exploring the Intersection of Health and Nutrition. Cham: Springer Nature Switzerland; 2025. p. 331-49. 978-3-031-94581-6/978-3-031-94582-3. 89. Elmas O, Aslan M, Caglar S, Derin N, Agar A, Aliciguzel Y, et al. The prooxidant effect of sodium metabisulfite in rat liver and kidney. Regul Toxicol Pharmacol. 2005;42(1):77-82. doi: https://doi.org/10.1016/j.yrtph.2005.01.010 90. Velayutham M, Hemann CF, Cardounel AJ, Zweier JL. Sulfite Oxidase Activity of Cytochrome c: Role of Hydrogen Peroxide. Biochem Biophys Rep. 2016;5:96-104. doi: https://doi.org/10.1016/j.bbrep.2015.11.025 91. United States Environmental Protection Agency. Inorganic Sulfites. Response to Public Comments on the Draft Human Health Risk Assessment in Support of Registration Review. Office Of Chemical Safety And Pollution Prevention. 2020. 92. Madsen CB, van den Dungen MW, Cochrane S, Houben GF, Knibb RC, Knulst AC, et al. Can we define a level of protection for allergic consumers that everyone can accept? Regul Toxicol Pharmacol. 2020;117:104751. doi: https://doi.org/10.1016/j.yrtph.2020.104751 93. Hajri Z, Chigr M, Oussama A, Kzaiber F, Boutoial K. Dietary exposure assessment to sulfites (SO2) in the Moroccan adult population. Food Research. 2023;7(6):1-10. doi: https://doi.org/10.26656/fr.2017.7(6).625 94. Seto T, Grondin JA, Khan WI. Food Additives: Emerging Detrimental Roles on Gut Health. FASEB J. 2025;39(13):e70810. doi: https://doi.org/10.1096/fj.202500737R 95. Lien KW, Hsieh DPH, Huang HY, Wu CH, Ni SP, Ling MP. Food safety risk assessment for estimating dietary intake of sulfites in the Taiwanese population. Toxicol Rep. 2016;3:544-51. doi: https://doi.org/10.1016/j.toxrep.2016.06.003 96. Jessurun NT, Wijnen PA, Bast A, van Puijenbroek EP, Bekers O, Drent M. Tamsulosin Associated with Interstitial Lung Damage in CYP2D6 Variant Alleles Carriers. International journal of molecular sciences. 2020;21(8). doi: https://doi.org/10.3390/ijms21082770 97. MacDonell MM, Hertzberg RC, Rice GE, Wright JM, Teuschler LK. Characterizing Risk for Cumulative Risk Assessments. Risk Anal. 2018;38(6):1183-201. doi: https://doi.org/10.1111/risa.12933 98. Guerrero RF, Cantos-Villar E. Demonstrating the efficiency of sulphur dioxide replacements in wine: A parameter review. Trends in Food Science & Technology. 2015;42(1):27-43. doi: https://doi.org/10.1016/j.tifs.2014.11.004 99. K. Quansah J, Kwesi Saalia F. Chemistry of Food Additives: Preservatives. In: Lagouri VS, editor. Food Additives - From Chemistry to Safety. Food Science and Nutrition. London: IntechOpen; 2024. 978-0-85014-429-1/978-0-85014-430-7. 100. Pizzorno JE, Murray MT. Textbook of Natural Medicine - E-Book: Textbook of Natural Medicine - E-Book: Churchill Livingstone; 2020. 9780323523806. 101. Molybdenum Cofactor Deficiency. In: Pascual JM, editor. Progressive Brain Disorders in Childhood. Cambridge: Cambridge University Press; 2017. p. 70-4. 9781107323704 Journal of Complementary Therapies in Health 2026: 4(1). 20 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 9781107042056/9781107686106. 102. Enns GM. Inborn errors of metabolism with features of hypoxic–ischemic encephalopathy. In: Stevenson DK, Benitz WE, Sunshine P, Hintz SR, Druzin ML, editors. Fetal and Neonatal Brain Injury. 4 ed. Cambridge: Cambridge University Press; 2009. p. 389-401. 9780521888592/9780511581281. 103. Mhanni AA, Greenberg CR, Spriggs EL, Agatep R, Sisk RR, Prasad C. Isolated sulfite oxidase deficiency: a founder mutation. Cold Spring Harb Mol Case Stud. 2020;6(6). doi: https://doi.org/10.1101/mcs.a005900 104. Tian M, Qu Y, Huang L, Su X, Li S, Ying J, et al. Stable clinical course in three siblings with late-onset isolated sulfite oxidase deficiency: a case series and literature review. BMC Pediatr. 2019;19(1):510. doi: https://doi.org/10.1186/s12887-019-1889-5 105. Tippairote T, Bjorklund G, Gasmi A, Semenova Y, Peana M, Chirumbolo S, et al. Combined Supplementation of Coenzyme Q(10) and Other Nutrients in Specific Medical Conditions. Nutrients. 2022;14(20). doi: https://doi.org/10.3390/nu14204383 106. Neacsu SM, Mititelu M, Ozon EA, Musuc AM, Iuga IDM, Manolescu BN, et al. Comprehensive Analysis of Novel Synergistic Antioxidant Formulations: Insights into Pharmacotechnical, Physical, Chemical, and Antioxidant Properties. Pharmaceuticals (Basel). 2024;17(6). doi: https://doi.org/10.3390/ph17060690 107. Cappelletti M, Pallotta L, Vona R, Tinari A, Pisano A, Casella G, et al. The Unexplored Role of Mitochondria-Related Oxidative Stress in Diverticular Disease. International journal of molecular sciences. 2024;25(17). doi: https://doi.org/10.3390/ijms25179680 108. Waldman H. Astaxanthin Supplementation as a Potential Strategy for Enhancing Mitochondrial Adaptations in the Endurance Athlete: An Invited Review. Nutrients. 2024;16(11). doi: https://doi.org/10.3390/nu16111750 109. Shahbazi A, Sepehrinezhad A, Vahdani E, Jamali R, Ghasempour M, Massoudian S, et al. Gut Dysbiosis and Blood-Brain Barrier Alteration in Hepatic Encephalopathy: From Gut to Brain. Biomedicines. 2023;11(5). doi: https://doi.org/10.3390/biomedicines11051272 110. Ozdemir A, Buyuktuncer Z. Dietary legumes and gut microbiome: a comprehensive review. Crit Rev Food Sci Nutr. 2025;65(28):5956-70. doi: https://doi.org/10.1080/10408398.2024.2434725 111. Bold J. Considerations for the diagnosis and management of sulphite sensitivity. Gastroenterol Hepatol Bed Bench. 2012;5(1):36. 112. Scheiber A, Mank V. Anti-inflammatory diets. 2023. 113. Fuad SA, Ginting RP, Lee M-W. Chrononutrition: Potential, Challenges, and Application in Managing Obesity. International journal of molecular sciences [Internet]. 2025; 26(11):[5116 p.]. doi: https://doi.org/10.3390/ijms26115116 114. Hodges RE, Minich DM. Modulation of Metabolic Detoxification Pathways Using Foods and Food-Derived Components: A Scientific Review with Clinical Application. J Nutr Metab. 2015;2015:760689. doi: https://doi.org/10.1155/2015/760689 115. Schwahn BC, van Spronsen F, Misko A, Pavaine J, Holmes V, Spiegel R, et al. Consensus guidelines for the diagnosis and management of isolated sulfite oxidase deficiency and molybdenum cofactor deficiencies. J Inherit Metab Dis. 2024;47(4):598623. doi: https://doi.org/10.1002/jimd.12730 116. Melinte O-E, Stavarache EI, Dobrin ME, Cernomaz AT, Cioroiu I-B, Popa DR, et al. Oxidative Stress and Risk Factors in Adult Patients with Bronchial Asthma: A Clinical Analysis of Representative Biomarkers. Journal of Clinical Medicine [Internet]. 2025; 14(11):[4007 p.]. doi: https://doi.org/10.3390/jcm14114007 117. Sanchez-Rodriguez MA, Mendoza-Nunez VM. Oxidative Stress Indexes for Diagnosis of Health or Disease in Humans. Oxid Med Cell Longev. 2019;2019:4128152. doi: https://doi.org/10.1155/2019/4128152 118. Mese O, Otsuka Y, Sakurada Y, Tokumasu K, Soejima Y, Morita S, et al. Clinical Evaluation of Oxidative Stress Markers in Patients with Long COVID During the Omicron Phase in Japan. Antioxidants (Basel). 2025;14(9). doi: https://doi.org/10.3390/antiox14091068 119. Johnson JL, Rajagopalan KV. An HPLC assay for detection of elevated urinary S-sulphocysteine, a metabolic marker of sulphite oxidase deficiency. J Inherit Metab Dis. 1995;18(1):40-7. doi: https://doi.org/10.1007/BF00711371 Journal of Complementary Therapies in Health 2026: 4(1). 21 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 120. Wroblewska J, Dlugosz A, Czarnecki D, Tomaszewicz W, Blaszak B, Szulc J, et al. The Role of Oxidative Stress in Skin Disorders Associated with Alcohol Dependency and Antioxidant Therapies. Molecules. 2025;30(15). doi: https://doi.org/10.3390/molecules30153111 121. Rawal R, Chawla S, Dahiya T, Pundir CS. Development of an amperometric sulfite biosensor based on a gold nanoparticles/chitosan/multiwalled carbon nanotubes/polyaniline-modified gold electrode. Anal Bioanal Chem. 2011;401(8):2599-608. doi: https://doi.org/10.1007/s00216-011-5325-4 122. Rajagopalan K. Sulfite oxidase (sulfite: ferricytochrome c oxidoreductase). Molybdenum and molybdenum-containing enzymes: Elsevier; 1980. p. 241-72. 123. Tejero J, Shiva S, Gladwin MT. Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation. Physiol Rev. 2019;99(1):311-79. doi: https://doi.org/10.1152/physrev.00036.2017 124. Johnson JL, Rajagopalan KV. The oxidation of sulphite in animals systems. Ciba Found Symp. 1979(72):119-33. doi: https://doi.org/10.1002/9780470720554.ch8 125. Brumaru D, Guerin E, Voegeli AC, Eyer D, Maitre M. A compound heterozygote case of isolated sulfite oxidase deficiency. Mol Genet Metab Rep. 2017;12:99-102. doi: https://doi.org/10.1016/j.ymgmr.2017.06.009 126. Bindu PS, Nagappa M, Bharath RD, Taly AB. Isolated sulfite oxidase deficiency. 2017. 127. Wang J, Krizowski S, Fischer-Schrader K, Niks D, Tejero J, Sparacino-Watkins C, et al. Sulfite Oxidase Catalyzes Single-Electron Transfer at Molybdenum Domain to Reduce Nitrite to Nitric Oxide. Antioxid Redox Signal. 2015;23(4):283-94. doi: https://doi.org/10.1089/ars.2013.5397 128. Kaufholdt D, Baillie CK, Meinen R, Mendel RR, Hansch R. The Molybdenum Cofactor Biosynthesis Network: In vivo ProteinProtein Interactions of an Actin Associated Multi-Protein Complex. Front Plant Sci. 2017;8:1946. doi: https://doi.org/10.3389/fpls.2017.01946 129. Mendel RR. The History of the Molybdenum Cofactor-A Personal View. Molecules. 2022;27(15). doi: https://doi.org/10.3390/molecules27154934 130. Jishi A, Qi X. Altered Mitochondrial Protein Homeostasis and Proteinopathies. Front Mol Neurosci. 2022;15:867935. doi: https://doi.org/10.3389/fnmol.2022.867935 131. Zhao S, Li Z, Liu K, Wang G, Wang Q, Yu H, et al. Combining multi-omics analysis with machine learning to uncover novel molecular subtypes, prognostic markers, and insights into immunotherapy for melanoma. BMC Cancer. 2025;25(1):630. doi: https://doi.org/10.1186/s12885-025-14012-3 132. Zhang Y, Wu D, Zeng X, Qiu B, Zhu Q, Zhang J. H(2)O(2) Production via Artificial Photosynthesis Over Defective Graphitic Carbon Nitride. Adv Sci (Weinh). 2025;12(33):e07913. doi: https://doi.org/10.1002/advs.202507913 133. Solomonson M, Setiaputra D, Makepeace KAT, Lameignere E, Petrotchenko EV, Conrady DG, et al. Structure of EspB from the ESX-1 type VII secretion system and insights into its export mechanism. Structure. 2015;23(3):571-83. doi: https://doi.org/10.1016/j.str.2015.01.002 134. Zhao J, An Y, Jiang H, Wu H, Che F, Yang Y. Novel Compound Heterozygous Pathogenic Variants in SUOX Cause Isolated Sulfite Oxidase Deficiency in a Chinese Han Family. Front Genet. 2021;12:607085. doi: https://doi.org/10.3389/fgene.2021.607085 135. Schwarz G, Belaidi AA. Molybdenum in human health and disease. Met Ions Life Sci. 2013;13:415-50. doi: https://doi.org/10.1007/978-94-007-7500-8_13 136. Johnson JL, Rajagopalan KV. The Oxidation of Sulphite in Animal Systems. Ciba Foundation Symposium 72 - Sulphur in Biology. Novartis Foundation Symposia1980. p. 119-33. 9780470720554. 137. Chronowski C, Akhanov V, Chan D, Catic A, Finegold M, Sahin E. Fructose Causes Liver Damage, Polyploidy, and Dysplasia in the Setting of Short Telomeres and p53 Loss. Metabolites. 2021;11(6). doi: https://doi.org/10.3390/metabo11060394 138. Sulfites as food additives. Nutr Rev. 1976;34(2):58-62. doi: https://doi.org/10.1111/j.1753-4887.1976.tb05697.x Journal of Complementary Therapies in Health 2026: 4(1). 22 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 139. Kaczmarek AT, Bender D, Gehling T, Kohl JB, Daimaguler HS, Santamaria-Araujo JA, et al. A defect in molybdenum cofactor binding causes an attenuated form of sulfite oxidase deficiency. J Inherit Metab Dis. 2022;45(2):169-82. doi: https://doi.org/10.1002/jimd.12454 140. Richardson K, Yonekawa K. Glomerulonephropathies and disorders of tubular function. Avery's Diseases of the Newborn: Elsevier; 2018. p. 1301-7. e2. 141. Singer HS, Mink JW, Gilbert DL, Jankovic J, Singer HS, Mink JW, et al. Chapter 17-metabolic disorders with associated movement abnormalities. Netherlands: Elsevier Inc. 2022:443-533. 142. Fujiwara T. [Pathophysiology of sideroblastic anemia]. Rinsho Ketsueki. 2024;65(9):911-9. doi: https://doi.org/10.11406/rinketsu.65.911 143. Lepore E, Lauretta R, Bianchini M, Mormando M, Di Lorenzo C, Unfer V. Inositols Depletion and Resistance: Principal Mechanisms and Therapeutic Strategies. International journal of molecular sciences. 2021;22(13). doi: https://doi.org/10.3390/ijms22136796 144. Sass JO, Gunduz A, Araujo Rodrigues Funayama C, Korkmaz B, Dantas Pinto KG, Tuysuz B, et al. Functional deficiencies of sulfite oxidase: Differential diagnoses in neonates presenting with intractable seizures and cystic encephalomalacia. Brain Dev. 2010;32(7):544-9. doi: https://doi.org/10.1016/j.braindev.2009.09.005 145. Ismail FY, Mitoma H, Fatemi A. Metabolic ataxias. Handb Clin Neurol. 2018;155:117-27. doi: https://doi.org/10.1016/B978-0-44464189-2.00008-1 146. de Vries BB, van'tHoff WG, Surtees RA, Winter RM. Diagnostic dilemmas in four infants with nephrotic syndrome, microcephaly and severe developmental delay. Clin Dysmorphol. 2001;10(2):115-21. doi: https://doi.org/10.1097/00019605-20010400000008 147. Kajiyama H, Nojima Y, Mitsuhashi H, Ueki K, Tamura S, Sekihara T, et al. Elevated levels of serum sulfite in patients with chronic renal failure. J Am Soc Nephrol. 2000;11(5):923-7. doi: https://doi.org/10.1681/ASN.V115923 148. Rashed MS, Saadallah AA, Rahbeeni Z, Eyaid W, Seidahmed MZ, Al-Shahwan S, et al. Determination of urinary S-sulphocysteine, xanthine and hypoxanthine by liquid chromatography-electrospray tandem mass spectrometry. Biomed Chromatogr. 2005;19(3):223-30. doi: https://doi.org/10.1002/bmc.439 149. Kinsinger M, Ivanisevic J, Mithal DS. Novel pathogenic variant in a mild case of type B molybdenum cofactor deficiency: case report and literature review. BMC Med Genomics. 2024;17(1):292. doi: https://doi.org/10.1186/s12920-024-02027-x 150. Hossain E, Sarkhel S, Mandal S, Biswas R. Application of nanotechnology in lysosomal storage diseases. Nanobiomaterials and Nanomedicines for Metabolic Disorders: Elsevier; 2026. p. 377-419. 151. Ghosh S, Singh KK, Raghunath M, Sinha JK. Clinical Trials and Evidence-Based Nutraceutical Interventions. In: Kumar Singh A, Nand Rai S, editors. Rejuvenating the Brain: Nutraceuticals, Autophagy, and Longevity. Nutritional Neurosciences. Singapore: Springer Nature Singapore; 2025. p. 427-55. 978-981-95-2789-2/978-981-95-2790-8. 152. Schwahn BC, Hart C, Smith LA, Hart A, Fairbanks L, Arenas-Hernandez M, et al. cPMP rescue of a neonate with severe molybdenum cofactor deficiency after serendipitous early diagnosis, and characterisation of a novel MOCS1 variant. Mol Genet Metab. 2024;143(4):108598. doi: https://doi.org/10.1016/j.ymgme.2024.108598 153. Choong CT, Hart C, Tan ES, Goh DLM. Clinical and laboratory barriers to the timely diagnosis of Sulphite oxidase deficiency. Proceedings of Singapore Healthcare. 2010;19(2):94-100. 154. Wadman SK, Duran M, Beemer FA, Cats BP, Johnson JL, Rajagopalan KV, et al. Absence of hepatic molybdenum cofactor: an inborn error of metabolism leading to a combined deficiency of sulphite oxidase and xanthine dehydrogenase. J Inherit Metab Dis. 1983;6 Suppl 1(1):78-83. doi: https://doi.org/10.1007/BF01811328 155. Belaidi AA, Schwarz G. Molybdenum Cofactor in Humans: Health, Disease, and Treatment. Molecular, genetic, and nutritional aspects of major and trace minerals. 2017:399-410. Journal of Complementary Therapies in Health 2026: 4(1). 23 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 156. Itrat N, Israr B, Arif S, Narjis M, Asghar S, Ali A. Nutrient Absorption Dynamics and Food Contamination. In: Sarkar T, Hamad A, Chatterjee A, editors. Physiological Perspectives on Food Safety: Exploring the Intersection of Health and Nutrition. Cham: Springer Nature Switzerland; 2025. p. 101-31. 978-3-031-94581-6/978-3-031-94582-3. 157. Toresson L, Steiner JM, Suchodolski JS. Cholestyramine treatment in two dogs with presumptive bile acid diarrhoea: a case report. Canine Med Genet. 2021;8(1):1. doi: https://doi.org/10.1186/s40575-021-00099-x 158. Zhou M, Li X, Wang X, Deng N, Cai Y, Tan Z. The dysfunction in intestinal microorganisms and enzyme activity as significant contributors to diarrhea with kidney-yang deficiency syndrome. Front Microbiol. 2023;14:1324938. doi: https://doi.org/10.3389/fmicb.2023.1324938 159. Wang X, Li Y, Zhao A, Wang Y, Cao Q, Pan C, et al. Next-generation sequencing through multi-gene panel testing for the diagnosis of a Chinese patient with atypical Cockayne syndrome. Mol Genet Genomic Med. 2023;11(11):e2254. doi: https://doi.org/10.1002/mgg3.2254 160. Wedge RA, Cartaxo T, Spicer CM, Volberding PA, National Academies of Sciences E, Medicine. Overview of Hereditary Disorders of Connective Tissue. Selected Heritable Disorders of Connective Tissue and Disability: National Academies Press (US); 2022. 161. Nelkowska DD. Treating irritable bowel syndrome through an interdisciplinary approach. Ann Gastroenterol. 2020;33(1):1-8. doi: https://doi.org/10.20524/aog.2019.0441 162. Mayer EA. The neurobiology of stress and gastrointestinal disease. Gut. 2000;47(6):861-9. doi: https://doi.org/10.1136/gut.47.6.861 163. Zuo XL, Li YQ, Li WJ, Guo YT, Lu XF, Li JM, et al. Alterations of food antigen-specific serum immunoglobulins G and E antibodies in patients with irritable bowel syndrome and functional dyspepsia. Clin Exp Allergy. 2007;37(6):823-30. doi: https://doi.org/10.1111/j.1365-2222.2007.02727.x 164. Knibb RC, Armstrong A, Booth DA, Platts RG, Booth IW, MacDonald A. Psychological characteristics of people with perceived food intolerance in a community sample. Journal of psychosomatic research. 1999;47(6):545-54. doi: https://doi.org/10.1016/s0022-3999(99)00055-0 165. Fu CY, Kohl JB, Liebsch F, D'Andrea D, Ditroi T, Ogata S, et al. Sulfite oxidase deficiency causes persulfidation loss and hydrogen sulfide release. J Clin Invest. 2025;135(21). doi: https://doi.org/10.1172/JCI181299 166. Zhang J, Zhang Z, Wang X, Liu Y, Yu Q, Wang K, et al. Connection between oxidative stress and subcellular organelle in subarachnoid hemorrhage: Novel mechanisms and therapeutic implications. CNS Neurosci Ther. 2023;29(12):3672-83. doi: https://doi.org/10.1111/cns.14348 167. Reist M, Marshall KA, Jenner P, Halliwell B. Toxic effects of sulphite in combination with peroxynitrite on neuronal cells. J Neurochem. 1998;71(6):2431-8. doi: https://doi.org/10.1046/j.1471-4159.1998.71062431.x 168. Liu M, Lu J, Chen Y, Zhang S, Guo J, Guan S. Sodium Sulfite-Triggered Hepatocyte Ferroptosis via mtROS/Lysosomal Membrane Permeabilization-Mediated Lysosome Iron Efflux. J Agric Food Chem. 2023;71(43):16310-22. doi: https://doi.org/10.1021/acs.jafc.3c06085 169. Suh H-J, Cho Y-H, Chung M-S, Hee Kim B. Preliminary data on sulphite intake from the Korean diet. Journal of Food Composition and Analysis. 2007;20(3-4):212-9. doi: https://doi.org/10.1016/j.jfca.2006.04.012 170. Cig B, Petit PX, Mayo JC. Ferroptosis: intersections, implications, and innovations in programmed cell death. Frontiers Media SA; 2025. p. 1635046. 171. Carvalho IM, Melo Cavalcante AA, Dantas AF, Pereira DL, Costa Rocha FC, Andrade TJ, et al. Genotoxicity of sodium metabisulfite in mouse tissues evaluated by the comet assay and the micronucleus test. Mutat Res. 2011;720(1-2):58-61. doi: https://doi.org/10.1016/j.mrgentox.2010.12.007 172. Pagnotta MA. Molecular Breeding for Abiotic Stress Tolerance in Crops: Recent Developments and Future Prospectives. International journal of molecular sciences. 2025;26(18). doi: https://doi.org/10.3390/ijms26189164 Journal of Complementary Therapies in Health 2026: 4(1). 24 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 173. Barton LL, Fardeau M-L, Fauque GD. Hydrogen Sulfide: A Toxic Gas Produced by Dissimilatory Sulfate and Sulfur Reduction and Consumed by Microbial Oxidation. In: Kroneck PMH, Torres MES, editors. The Metal-Driven Biogeochemistry of Gaseous Compounds in the Environment. Dordrecht: Springer Netherlands; 2014. p. 237-77. 978-94-017-9269-1. 174. Dovrou E, Bates KH, Rivera-Rios JC, Cox JL, Shutter JD, Keutsch FN. Towards a chemical mechanism of the oxidation of aqueous sulfur dioxide via isoprene hydroxyl hydroperoxides (ISOPOOH). Atmospheric Chemistry and Physics. 2021;21(11):89999008. doi: https://doi.org/10.5194/acp-21-8999-2021 175. Li Y, Park JS, Deng JH, Bai Y. Cytochrome c oxidase subunit IV is essential for assembly and respiratory function of the enzyme complex. J Bioenerg Biomembr. 2006;38(5-6):283-91. doi: https://doi.org/10.1007/s10863-006-9052-z 176. Yamashita T, Voth GA. Insights into the mechanism of proton transport in cytochrome c oxidase. J Am Chem Soc. 2012;134(2):1147-52. doi: https://doi.org/10.1021/ja209176e 177. Kumar A, Dejanovic B, Hetsch F, Semtner M, Fusca D, Arjune S, et al. S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency. J Clin Invest. 2017;127(12):4365-78. doi: https://doi.org/10.1172/JCI89885 178. Bayram E, Topcu Y, Karakaya P, Yis U, Cakmakci H, Ichida K, et al. Molybdenum cofactor deficiency: review of 12 cases (MoCD and review). Eur J Paediatr Neurol. 2013;17(1):1-6. doi: https://doi.org/10.1016/j.ejpn.2012.10.003 179. Edwards M, Roeper J, Allgood C, Chin R, Santamaria J, Wong F, et al. Investigation of molybdenum cofactor deficiency due to MOCS2 deficiency in a newborn baby. Meta Gene. 2015;3:43-9. doi: https://doi.org/10.1016/j.mgene.2014.12.003 180. Sanghai N, Tranmer GK. Biochemical and Molecular Pathways in Neurodegenerative Diseases: An Integrated View. Cells. 2023;12(18). doi: https://doi.org/10.3390/cells12182318 181. Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov. 2007;6(11):917-35. doi: https://doi.org/10.1038/nrd2425 182. Ezenwosu SU, Nnamonu EI, Odo GE, Ikele BC, Ani OC. Evaluation of lambda-cyhalothrin oxidative stress and gonad histoarchitecture toxicity potency in Clarias gariepinus. The Journal of Basic and Applied Zoology. 2021;82(1):3. doi: https://doi.org/10.1186/s41936-020-00201-y 183. Bouillaud F. Sulfide Oxidation Evidences the Immediate Cellular Response to a Decrease in the Mitochondrial ATP/O(2) Ratio. Biomolecules. 2022;12(3). doi: https://doi.org/10.3390/biom12030361 184. Zare S, Hossein Dabbaghmanesh M, Noorafshan A, Koohpeyma F, Bakhshayeshkaram M, Montazeri-Najafabady N. Protective effect of vitamin E and vitamin C alone and in combination on testicular damage induced by sodium metabisulphite in rats: A stereological study. Andrologia. 2019;51(2):e13193. doi: https://doi.org/10.1111/and.13193 185. Gabbay DS, De Roos F, Perrone J. Twenty-foot fall averts fatality from massive hydrogen sulfide exposure. J Emerg Med. 2001;20(2):141-4. doi: https://doi.org/10.1016/s0736-4679(00)00301-2 186. Edwards MC, Johnson JL, Marriage B, Graf TN, Coyne KE, Rajagopalan KV, et al. Isolated sulfite oxidase deficiency: review of two cases in one family. Ophthalmology. 1999;106(10):1957-61. doi: https://doi.org/10.1016/S0161-6420(99)90408-6 187. Irwin SV, Fisher P, Graham E, Malek A, Robidoux A. Sulfites inhibit the growth of four species of beneficial gut bacteria at concentrations regarded as safe for food. PloS one. 2017;12(10):e0186629. doi: https://doi.org/10.1371/journal.pone.0186629 188. Tan WH, Eichler FS, Hoda S, Lee MS, Baris H, Hanley CA, et al. Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature. Pediatrics. 2005;116(3):757-66. doi: https://doi.org/10.1542/peds.2004-1897 189. Sadek AA, Aladawy MA, Magdy RM, Fouad MF, Mansour TMM, Gad EF, et al. Urinary stones as the initial presentation in a child with late-onset molybdenum cofactor deficiency type B: a case report and review of literature. Egyptian Journal of Medical Human Genetics. 2025;26(1):102. doi: https://doi.org/10.1186/s43042-025-00720-9 190. Furuto Y, Kawamura M, Namikawa A, Takahashi H, Shibuya Y, Mori T, et al. Non-urate transporter 1, non-glucose transporter member 9-related renal hypouricemia and acute renal failure accompanied by hyperbilirubinemia after anaerobic exercise: a case report. BMC Nephrol. 2019;20(1):433. doi: https://doi.org/10.1186/s12882-019-1618-1 Journal of Complementary Therapies in Health 2026: 4(1). 25 of 28 Afonso R., Veiga J., Almeida T., Barros J.A., Peixoto M. Molybdenum and Sulphite Detoxification: Biochemical Foundations and Clinical Implications for Integrative Practice. doi:10.5281/zenodo.17976742 191. Kardah H, Al-Zoubi H, Odeh Z, Joumaa R, Alasmar D. A case report of molybdenum cofactor deficiency type A: the first case diagnosed in Syria. Ann Med Surg (Lond). 2024;86(3):1762-5. doi: https://doi.org/10.1097/MS9.0000000000001778 192. Claerhout H, Witters P, Regal L, Jansen K, Van Hoestenberghe MR, Breckpot J, et al. Isolated sulfite oxidase deficiency. J Inherit Metab Dis. 2018;41(1):101-8. doi: https://doi.org/10.1007/s10545-017-0089-4 193. Kampen KR, Sulima SO, Vereecke S, De Keersmaecker K. Hallmarks of ribosomopathies. Nucleic Acids Res. 2020;48(3):101328. doi: https://doi.org/10.1093/nar/gkz637 194. Carbajo JM, Maraver F. Sulphurous Mineral Waters: New Applications for Health. Evidence-based complementary and alternative medicine : eCAM. 2017;2017:8034084. doi: https://doi.org/10.1155/2017/8034084 195. Tutuncu B, Kucukatay V, Arslan S, Sahin B, Semiz A, Sen A. Alteration of drug metabolizing enzymes in sulphite oxidase deficiency. J Clin Biochem Nutr. 2012;51(1):50-4. doi: https://doi.org/10.3164/jcbn.11-79 196. Hildebrandt TM, Grieshaber MK. Three enzymatic activities catalyze the oxidation of sulfide to thiosulfate in mammalian and invertebrate mitochondria. FEBS J. 2008;275(13):3352-61. doi: https://doi.org/10.1111/j.1742-4658.2008.06482.x 197. Müller FH, Bandeiras TM, Urich T, Teixeira M, Gomes CM, Kletzin A. Coupling of the pathway of sulphur oxidation to dioxygen reduction: characterization of a novel membrane-bound thiosulphate: quinone oxidoreductase. Molecular microbiology. 2004;53(4):1147-60. 198. Enemark JH. Mechanistic complexities of sulfite oxidase: An enzyme with multiple domains, subunits, and cofactors. J Inorg Biochem. 2023;247:112312. doi: https://doi.org/10.1016/j.jinorgbio.2023.112312 199. Kocamaz E, Adiguzel E, Er B, Gundogdu G, Kucukatay V. Sulfite leads to neuron loss in the hippocampus of both normal and SOX-deficient rats. Neurochem Int. 2012;61(3):341-6. doi: https://doi.org/10.1016/j.neuint.2012.06.010 200. Sugahara K, Kitagawa H. Heparin and heparan sulfate biosynthesis. IUBMB Life. 2002;54(4):163-75. doi: https://doi.org/10.1080/15216540214928 201. Markovich D. Physiological roles and regulation of mammalian sulfate transporters. Physiol Rev. 2001;81(4):1499-533. doi: https://doi.org/10.1152/physrev.2001.81.4.1499 202. Xu P, Cai X, Guan X, Xie W. Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases. Pharmacol Ther. 2023;251:108540. doi: https://doi.org/10.1016/j.pharmthera.2023.108540 203. Powers HJ, Corfe BM, Nakano E. Riboflavin in development and cell fate. Subcell Biochem. 2012;56:229-45. doi: https://doi.org/10.1007/978-94-007-2199-9_12 204. Sekhar RV, Patel SG, Guthikonda AP, Reid M, Balasubramanyam A, Taffet GE, et al. Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. Am J Clin Nutr. 2011;94(3):84753. doi: https://doi.org/10.3945/ajcn.110.003483 205. Rubino FM. Toxicity of Glutathione-Binding Metals: A Review of Targets and Mechanisms. Toxics. 2015;3(1):20-62. doi: https://doi.org/10.3390/toxics3010020 206. Toppo S, Flohe L, Ursini F, Vanin S, Maiorino M. Catalytic mechanisms and specificities of glutathione peroxidases: variations of a basic scheme. Biochim Biophys Acta. 2009;1790(11):1486-500. doi: https://doi.org/10.1016/j.bbagen.2009.04.007 207. Zachara BA, Gromadzinska J, Wasowicz W, Zbrog Z. Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: a review. Acta Biochim Pol. 2006;53(4):663-77. 208. Zhang X, Liu H, Hao Y, Xu L, Zhang T, Liu Y, et al. Coenzyme Q10 protects against hyperlipidemia-induced cardiac damage in apolipoprotein E-deficient mice. Lipids Health Dis. 2018;17(1):279. doi: https://doi.org/10.1186/s12944-018-0928-9 209. Cai Y, Yang Z. Ferroptosis and Its Role in Epilepsy. Front Cell Neurosci. 2021;15:696889. doi: https://doi.org/10.3389/fncel.2021.696889 210. Della Croce C, Bronzetti G, Cini M, Caltavuturo L, Poi G. Protective effect of lipoic acid against hydrogen peroxide in yeast cells. Toxicol In Vitro. 2003;17(5-6):753-9. doi: https://doi.org/10.1016/j.tiv.2003.06.001